http://unclineberger.org/unc-cancer-network/lunch-and-learn-media-page (Click link)
Showing posts with label Dr. Lisa Carey. Show all posts
Showing posts with label Dr. Lisa Carey. Show all posts
Monday, October 28, 2013
Dr. Lisa Carey Triple Negative Breast Cancer Q&A Teleconference 2013
http://unclineberger.org/unc-cancer-network/lunch-and-learn-media-page (Click link)
Saturday, January 5, 2013
Triple Negative Breast Cancer Foundation's Interview With Lisa Carey, MD, Medical Director Of The Breast Center At The University Of North Carolina
News from the San Antonio Breast Cancer Symposium 2012
Lisa Carey, MD, Medical Director of the Breast Center at the University of North Carolina comments on this year's Symposium.Thursday, December 7, 2012
I wouldn't say that there is anything that has been presented this year that is going to have an immediate impact on how we treat triple negative breast cancer patients, today, but, overall, I see great promise for the future. The data related to deep genomic analysis are just exploding.
I know that is hard for patients who are waiting for a major step forward, but we aren't there yet in terms of the big phase III trial because the targets aren't clear at this point. In fact, triple negative breast cancer is going to lead the way in changing how we think about cancer and how we treat it. Right now, we usually start with the disease. You have stage IIb, HER2+ breast cancer, for example-and we treat that disease. With triple negative breast cancer, and probably many others as well, we need to start with the person, with the individual tumor. We need to sequence that tumor and identify the genes that are driving it. That's a significant change.
I think that in the next few years, we will have a panel of breast cancer genes and we will sequence every patient and treat what is there. If you look at the HER2 study that Ron Bose presented today or the new data on LAR TNBC, you can see that we have already identified some actionable targets. These may occur in small subsets of patients, but they are opening new doors to treatment that we will see in the near future.
The other thing I want to stress to today's patients is that we can often treat your disease successfully right now with conventional therapy. We get very good results for early TNBC. I think you can see that in what appears to be a negative study on the benefits, or lack thereof, of bevacizumab for adjuvant therapy. The overall survival rate exceeded the study's expectations, and I think that this reflects an improvement in treatment and outcomes for these patients. I have patients come to me who have read about TNBC on the web and think they are doomed, but the reality is that we have effective therapy for early TNBC and these patients often do very well.
There are many unmet needs for TNBC and a real need to develop these genomically based therapies, but I think there is progress now-and there will be much more in the future.
I wouldn't say that there is anything that has been presented this year that is going to have an immediate impact on how we treat triple negative breast cancer patients, today, but, overall, I see great promise for the future. The data related to deep genomic analysis are just exploding.
I know that is hard for patients who are waiting for a major step forward, but we aren't there yet in terms of the big phase III trial because the targets aren't clear at this point. In fact, triple negative breast cancer is going to lead the way in changing how we think about cancer and how we treat it. Right now, we usually start with the disease. You have stage IIb, HER2+ breast cancer, for example-and we treat that disease. With triple negative breast cancer, and probably many others as well, we need to start with the person, with the individual tumor. We need to sequence that tumor and identify the genes that are driving it. That's a significant change.
I think that in the next few years, we will have a panel of breast cancer genes and we will sequence every patient and treat what is there. If you look at the HER2 study that Ron Bose presented today or the new data on LAR TNBC, you can see that we have already identified some actionable targets. These may occur in small subsets of patients, but they are opening new doors to treatment that we will see in the near future.
The other thing I want to stress to today's patients is that we can often treat your disease successfully right now with conventional therapy. We get very good results for early TNBC. I think you can see that in what appears to be a negative study on the benefits, or lack thereof, of bevacizumab for adjuvant therapy. The overall survival rate exceeded the study's expectations, and I think that this reflects an improvement in treatment and outcomes for these patients. I have patients come to me who have read about TNBC on the web and think they are doomed, but the reality is that we have effective therapy for early TNBC and these patients often do very well.
There are many unmet needs for TNBC and a real need to develop these genomically based therapies, but I think there is progress now-and there will be much more in the future.
Christine Wilson for TNBC Foundation
Thursday, June 16, 2011
My Visit Accompanying My TNBC Sister To Her Appointment With Dr. Lisa Carey in Chapel Hill, NC
Dr. Carey is who I look to for ALL my answers...
she's really one of the TNBC heroes we have." - Vickie Roy-Sneddon
 |
| I accompanied my TNBC sister, Tracy who had a recurrence a year later and is now terminal. Looking to Dr. Lisa Carey for answers, it was a little disheartening knowing she can't cure her 2nd time around. |
 |
It was a pleasure meeting DR. Carey whom I
admire and respect...
This is my Tracy... fighting for her quality of life.
"Take the very breath You gave me. Take the heart from my chest. I'll gladly take her place if you'll let me, Make this my last request. Take me out of this world God, please don't take the girl" - Tim Mcgraw |
Friday, April 29, 2011
Dr. Lisa Carey, World-Wide Expert In Triple Negative Breast Cancer
| Lisa A. Carey, M.D.
Associate Professor
Breast Cancer Hematology/Oncology |  |
Clinical Interests
Dr. Carey is board-certified in both Internal Medicine and Medical Oncology. Her clinical interest is in breast cancer, and she is the Medical Director of the UNC Breast Center.
Dr. Carey is board-certified in both Internal Medicine and Medical Oncology. Her clinical interest is in breast cancer, and she is the Medical Director of the UNC Breast Center.
Research Interests
Dr. Carey's research interests also focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy.
Dr. Carey has worked extensively with scientists across Lineberger Comprehensive Cancer Center and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype. She is now the leader of a group of UNC clinician researchers using a variety of new drugs in different molecular subtypes of breast cancer based upon biologic information learned from scientists at Lineberger.
For example, the members of the UNC Breast Center have a long commitment to improving treatment of early (nonmetastatic) breast cancer, and have been early investigators in the use of neoadjuvant, or preoperative, chemotherapy for breast cancer. In part based upon work performed at UNC, we now know that women do just as well if their chemotherapy is given before surgery as after, however the chemotherapy-first approach means that they are more likely to save their breast. In addition, with preoperative therapy it is possible to tell if the drugs are working since the tumor is still measurable when the chemotherapy is given first. Part of Dr. Carey's clinical research program investigates new drugs and combination of drugs in preoperative therapy. As part of this neoadjuvant chemotherapy program, she is involved in several studies, including a multiinstitutional trial sponsored by the National Cancer Institute, of genetic and molecular markers in breast cancer as predictors of response to chemotherapy, and she is the lead investigator of a national study of new drug combinations in HER2-positive breast cancer.
Dr. Carey is also the principal investigator of a highly collaborative study examining genes that might interact with other genes or with the environment to impact on a woman's risk of developing breast cancer.
Dr. Carey's research interests also focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy.
Dr. Carey has worked extensively with scientists across Lineberger Comprehensive Cancer Center and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype. She is now the leader of a group of UNC clinician researchers using a variety of new drugs in different molecular subtypes of breast cancer based upon biologic information learned from scientists at Lineberger.
For example, the members of the UNC Breast Center have a long commitment to improving treatment of early (nonmetastatic) breast cancer, and have been early investigators in the use of neoadjuvant, or preoperative, chemotherapy for breast cancer. In part based upon work performed at UNC, we now know that women do just as well if their chemotherapy is given before surgery as after, however the chemotherapy-first approach means that they are more likely to save their breast. In addition, with preoperative therapy it is possible to tell if the drugs are working since the tumor is still measurable when the chemotherapy is given first. Part of Dr. Carey's clinical research program investigates new drugs and combination of drugs in preoperative therapy. As part of this neoadjuvant chemotherapy program, she is involved in several studies, including a multiinstitutional trial sponsored by the National Cancer Institute, of genetic and molecular markers in breast cancer as predictors of response to chemotherapy, and she is the lead investigator of a national study of new drug combinations in HER2-positive breast cancer.
Dr. Carey is also the principal investigator of a highly collaborative study examining genes that might interact with other genes or with the environment to impact on a woman's risk of developing breast cancer.
Recent Accomplishments and Honors
For her work, she was awarded a Doris Duke Clinical Scientist Award in 1999, a career development award from the National Cancer Institute in 2000, was inducted into the Johns Hopkins Society of Scholars in 2008, and was honored to serve as UNC?s commencement speaker in December, 2009.
For her work, she was awarded a Doris Duke Clinical Scientist Award in 1999, a career development award from the National Cancer Institute in 2000, was inducted into the Johns Hopkins Society of Scholars in 2008, and was honored to serve as UNC?s commencement speaker in December, 2009.
Training
M.D., Johns Hopkins School of Medicine 1990
Resident, Internal Medicine, Johns Hopkins 1990-3
Fellow, Medical Oncology, Johns Hopkins 1993-8
Sc.M., Clinical Investigations, Johns Hopkins School of Public Health 1994-8
M.D., Johns Hopkins School of Medicine 1990
Resident, Internal Medicine, Johns Hopkins 1990-3
Fellow, Medical Oncology, Johns Hopkins 1993-8
Sc.M., Clinical Investigations, Johns Hopkins School of Public Health 1994-8
Bio:
Lisa Carey is an Associate Professor in the UNC Department of Medicine, Division of Hematology-Oncology. She graduated from Wellesley College in 1984 with a BA in Biology and Art History, before receiving a MS in Physiology from the University of Kentucky. She received an MD from the Johns Hopkins University School of Medicine in 1990. After a residency in Internal Medicine also at Johns Hopkins, she stayed at Johns Hopkins for a fellowship in Medical Oncology. During her fellowship she completed a ScM. in Clinical Research. Dr. Carey joined the UNC faculty in 1998. She has served since 2003 as the Medical Director of the UNC Breast Center and is the UNC-Lineberger Comprehensive Cancer Center (UNC-LCCC) Protocol Office Executive Committee Breast Disease Group Leader as well as the UNC-LCCC Protocol Review Committee Breast Cancer Chair.
Dr. Carey has a well-defined interest in clinical/translational research in breast cancer, with a particular interest in the clinical implications of different molecular subtypes of breast cancer. She both designs and leads clinical trials as well as working often and well with laboratory investigators. She has successfully translated bench efforts from laboratory science collaborators into clinical research. She was the lead author of a recently published article in JAMA examining racial disparities among breast cancer subtypes. She is the principal investigator (P.I.) of several clinical trials, including a multicenter inter-SPORE (Specialized Program of Research Excellence, National Cancer Institute [NCI]) Phase II study of targeted therapy in metastatic basal-like breast cancer (a subtype identified by gene expression array). This heavily funded trial includes both clinical and laboratory participation from UCSF, Dana Farber, Duke University, Georgetown, Johns Hopkins, Baylor, Washington University, University of Alabama-Birmingham, Mayo, and M.D. Anderson Cancer Center, and is a testament to her ability to provide clinical leadership in translational and early clinical research.
Dr. Carey is the P.I. of a recently published multicenter Phase II study incorporating biologic therapy into chemotherapy for locally advanced breast cancer as well as a proposed cooperative group neoadjuvant trial examining several HER2-targeted strategies for Stage II-III HER2-positive breast cancer. She is the clinical liaison for several correlative science collaborations, including both institutional and cooperative group trials that correlate nucleic acid and protein characterization of breast cancers with response to neoadjuvant therapy.
Dr. Carey has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee and as faculty for the ASCO annual meeting for several years. She was named to the Cancer and Leukemia Group B (CALGB) Breast Core Committee in 2003. She was awarded a Doris Duke Clinician Scientist Award in 1999 and a Career Development Award from the NCI in 2000.
Lisa Carey is an Associate Professor in the UNC Department of Medicine, Division of Hematology-Oncology. She graduated from Wellesley College in 1984 with a BA in Biology and Art History, before receiving a MS in Physiology from the University of Kentucky. She received an MD from the Johns Hopkins University School of Medicine in 1990. After a residency in Internal Medicine also at Johns Hopkins, she stayed at Johns Hopkins for a fellowship in Medical Oncology. During her fellowship she completed a ScM. in Clinical Research. Dr. Carey joined the UNC faculty in 1998. She has served since 2003 as the Medical Director of the UNC Breast Center and is the UNC-Lineberger Comprehensive Cancer Center (UNC-LCCC) Protocol Office Executive Committee Breast Disease Group Leader as well as the UNC-LCCC Protocol Review Committee Breast Cancer Chair.
Dr. Carey has a well-defined interest in clinical/translational research in breast cancer, with a particular interest in the clinical implications of different molecular subtypes of breast cancer. She both designs and leads clinical trials as well as working often and well with laboratory investigators. She has successfully translated bench efforts from laboratory science collaborators into clinical research. She was the lead author of a recently published article in JAMA examining racial disparities among breast cancer subtypes. She is the principal investigator (P.I.) of several clinical trials, including a multicenter inter-SPORE (Specialized Program of Research Excellence, National Cancer Institute [NCI]) Phase II study of targeted therapy in metastatic basal-like breast cancer (a subtype identified by gene expression array). This heavily funded trial includes both clinical and laboratory participation from UCSF, Dana Farber, Duke University, Georgetown, Johns Hopkins, Baylor, Washington University, University of Alabama-Birmingham, Mayo, and M.D. Anderson Cancer Center, and is a testament to her ability to provide clinical leadership in translational and early clinical research.
Dr. Carey is the P.I. of a recently published multicenter Phase II study incorporating biologic therapy into chemotherapy for locally advanced breast cancer as well as a proposed cooperative group neoadjuvant trial examining several HER2-targeted strategies for Stage II-III HER2-positive breast cancer. She is the clinical liaison for several correlative science collaborations, including both institutional and cooperative group trials that correlate nucleic acid and protein characterization of breast cancers with response to neoadjuvant therapy.
Dr. Carey has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee and as faculty for the ASCO annual meeting for several years. She was named to the Cancer and Leukemia Group B (CALGB) Breast Core Committee in 2003. She was awarded a Doris Duke Clinician Scientist Award in 1999 and a Career Development Award from the NCI in 2000.
E-mail: Lisa_Carey@med.unc.edu
Telephone: (919) 966-4431
FAX: (919) 966-6735
Address: 3009 Old Clinic Bldg. Chapel Hill, NC 27599-7305
FAX: (919) 966-6735
Address: 3009 Old Clinic Bldg. Chapel Hill, NC 27599-7305
Biologic Differences in Breast Cancer: An Expert Interview With Dr. Lisa Carey http://www.medscape.org/viewarticle/572082
Next Generation Treatment for Triple-Negative and Basal-Cell Breast Cancer http://www.cancernetwork.com/conference-reports/mbcc2011/content/article/10165/1817148
List of Triple-Negative Sensitive Genotoxic Agents
Cyclophosphamide (Cytoxan)
Carboplatin (Paraplatin)
Cisplatin (Platinol)
Doxorubicin (Adriamycin)
Epirubicin (Ellence)
Mitomycin C (MTC / Mitomycin / Mutamycin)
Radiation (Radiotherapy
PARP Inhibitors
Wednesday, April 27, 2011
Subscribe to:
Posts (Atom)
"click image to link"